Sugi Predict

Sugi Predict / Compounds / Phenylthiourea

Phenylthiourea

Phenylthiourea

SCHEMBL1387782

N=C(S)Nc1ccccc1

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 4/20 0.50
▸ TAS2R38 P59533 3/20 0.50
▸ ALDH1A1 P00352 3/20 0.50
▸ TP53 P04637 2/20 0.50
▸ TSHR P16473 2/20 0.50
▸ EPHX1 P07099 1/20 0.50
▸ EPHX2 P34913 1/20 0.50
▸ CDK9 P50750 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ CLK4 Q9HAZ1 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ GAA P10253 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ NOX1 Q9Y5S8 1/20 0.46
▸ TYR P14679 1/20 0.46
▸ NAPRT Q6XQN6 1/20 0.46
▸ PHGDH O43175 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenylthiourea SCHEMBL4752639 0.97 HSD17B10 (0.48) HSD17B10TAS2R38ALDH1A1TP53TSHR
Phenylthiourea SCHEMBL1286887 0.97 HSD17B10 (0.48) HSD17B10TAS2R38ALDH1A1TP53TSHR
Phenylthiourea SCHEMBL29137480 0.84 NAPRT (0.53) HSD17B10TAS2R38ALDH1A1TP53TSHR
SCHEMBL9701953 0.78 FABP4 (0.47) HSD17B10ALDH1A1TP53TSHRCYP3A4
SCHEMBL35172 0.78 HSD17B10 (0.55) HSD17B10TAS2R38ALDH1A1TP53TSHR
SCHEMBL20163213 0.78 HSD17B10 (0.55) HSD17B10TAS2R38ALDH1A1TP53TSHR
Bromide SCHEMBL473887 0.76 TAS2R38 (0.52) HSD17B10TAS2R38ALDH1A1TP53TSHR
Fluoride SCHEMBL20815438 0.76 TAS2R38 (0.52) HSD17B10TAS2R38ALDH1A1TP53TSHR
SCHEMBL31160596 0.76 TAS2R38 (0.52) HSD17B10TAS2R38ALDH1A1TP53TSHR
SCHEMBL5819282 0.76 HSD17B10 (0.52) HSD17B10TAS2R38ALDH1A1TP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-H09504278-A — — 1997-04-28 — — JP claimed
EP-0723438-A1 SUBSTITUTED UREA AND ISOTHIOUREA DERIVATIVES AS NO SYNTHASE INHIBITORS THE WELLCOME FOUNDATION LIMITED (GB) 1996-07-31 — — EP claimed
WO-1995009619-A2 SUBSTITUTED UREA AND ISOTHIOUREA DERIVATIVES AS NO SYNTHASE INHIBITORS THE WELLCOME FOUNDATION LIMITED (GB) 1995-04-13 — — WO claimed
CN-116970697-A Use of SLC26A2 mutation in diagnosis of multiple epiphyseal dysplasia 北京市创伤骨科研究所 2023-10-31 — — CN disclosed
CN-113299866-B Film layer and preparation method thereof, and light-emitting device and preparation method thereof 合肥福纳科技有限公司 2023-04-07 — — CN disclosed
CN-114957438-A Human Abeta 1-42 antigenic determinant polypeptide for detecting Alzheimer disease and preparation method thereof 亿彤科技发展(福建)有限公司 2022-08-30 — — CN disclosed
CN-114920851-A Abeta 1-42 antigen and application thereof in detecting Abeta 1-42 concentration in Alzheimer patient 亿彤科技发展(福建)有限公司 2022-08-19 — — CN disclosed
WO-2017101793-A1 1, 3, 4-SELENADIAZOLE COMPOUNDS WITH PHARMACOLOGICAL ACTIVITY HANGZHOU JENNIFER BIOTECH CO., LTD. (CN) 2017-06-22 — — WO disclosed
US-20130289083-A1 IDO Inhibitors NEWLINK GENETICS CORPORATION 2013-10-31 — — US disclosed
WO-2012065213-A1 SELF-HEALING POLYMER NANOCOMPOSITES AND PROCESS FOR THE PREPARATION THEREOF DEAKIN UNIVERSITY (AU) 2012-05-24 — — WO disclosed
EP-2346515-A1 SPINAL CORD INJURY, INFLAMMATION, AND IMMUNE-DISEASE: LOCAL CONTROLLED RELEASE OF THERAPEUTIC AGENTS Invivo Therapeutics Corporation (US) 2011-07-27 — — EP disclosed
US-4914098-A INSECTICIDES, MITICIDES CIBA-GEIGY CORPORATION (US) 1990-04-03 — — US disclosed
US-4888348-A PESTICIDES CIBA-GEIGY CORPORATION (US) 1989-12-19 — — US disclosed
EP-0256985-A2 Substituted thio ureas, isothio ureas and carbodiimides CIBA-GEIGY AG (CH) 1988-02-24 — — EP disclosed
US-4262125-A ANTISECRETORY, HYPOTENSIVE AMERICAN HOME PRODUCTS CORPORATION (US) 1981-04-14 — — US disclosed
US-4021571-A ANTHELMINTICS BAYER AKTIENGESELLSCHAFT (DT) 1977-05-03 — — US disclosed
US-4021571-A ANTHELMINTICS BAYER AKTIENGESELLSCHAFT (DT) 1977-05-03 — — US disclosed
US-4005123-A ANTHELMINTIC AGENTS BAYER AKTIENGESELLSCHAFT (DT) 1977-01-25 — — US disclosed
US-4005123-A ANTHELMINTIC AGENTS BAYER AKTIENGESELLSCHAFT (DT) 1977-01-25 — — US disclosed
US-3931216-A Process for the manufacture of 2-arylamino-2-imidazoline derivatives and their salts BOEHRINGER INGELHEIM GMBH (DT) 1976-01-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130289083-A1 IDO Inhibitors IDO1, IDO2, INMT HSD17B10 1252/4885TAS2R38 4824/4885ALDH1A1 1238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.